Testing Serum Vitamin D Levels
Customize your policy alerts
Sign up for all blue cross blue shield - kansas policy alerts
Know when blue cross blue shield - kansas releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs when measurement of serum 25-hydroxyvitamin D is considered medically necessary, investigational, or routine screening for Blue Cross and Blue Shield of Kansas members; it applies to clinicians ordering vitamin D testing for insured members.
Changed Policy Statement C and D from not medically necessary to experimental / investigational.
Coverage Criteria and Evidence Summary
Medically necessary — high-risk conditions
Covered when ANY of the following high-risk conditions or scenarios are present
High-risk conditions for medically necessary testing
- Listed high-risk factors: 1. Chronic kidney disease, stage >=3; 2. Granulomatous diseases; 3. Parathyroid disorders; 4. Cirrhosis and chronic liver disease; 5. Malabsorption states; 6. Chronic use of anticonvulsant medications or systemic corticosteroids; 7. Osteomalacia; 8. Osteopenia; 9. Osteoporosis; 10. Rickets; 11. Vitamin D deficiency, on replacement; 12. Hypo- or hypercalcemia; 13. Obstructive jaundice/biliary tract disease; 14. Osteogenesis imperfecta; 15. Osteosclerosis and osteopetrosis.
From Policy Item A in the document.
Medically necessary — asymptomatic but at-risk or institutionalized
Covered in asymptomatic individuals when ALL of the following apply
Asymptomatic individuals at-risk or institutionalized
- Population conditions: 1) The individual has one or more risk factors for vitamin D deficiency (as listed under high-risk factors); AND 2) The individual is institutionalized (resides in a long-term care facility, long-term hospital stay, nursing home, assisted living, or similar setting).
Institutionalized defined in Policy Guidelines.
Experimental / Investigational / Routine screening — Not covered / investigational
Not covered / investigational
Policy Items C and D.
Overall clinical utility
General evidence summary relevant to coverage decisions
Analytic framework and 'Clinically Useful' summary.
Skeletal health
Skeletal health-specific findings relevant to coverage
Dose-response and subgroup signals noted; overall evidence not convincingly favorable.
Cardiovascular disease
Cardiovascular and other outcomes
Evidence summarized in cardiovascular section.
Cancer
Cancer outcomes
Cancer section summary.
Evidence-based considerations for testing
Guidance and evidence summaries relevant to when testing or supplementation may be considered:
ACOG committee opinion and pregnancy evidence summary.
Condition-specific evidence varies.
Guideline positions summarized.
Policy statement changes
Policy scope and notable policy statement changes (partial content from this document segment):
Revision history entries document these changes.
Routine population screening for vitamin D deficiency (testing asymptomatic individuals with no listed risk factors or institutionalization) is considered experimental/investigational and is excluded from coverage under this policy. The policy specifies that testing is medically necessary only when one of the defined high‑risk factors is present or when asymptomatic individuals meet the policy’s specific at‑risk or institutionalized criteria; otherwise routine screening is not covered.
There is no accepted reference standard or consensus cutoffs for defining vitamin D deficiency. Available 25‑hydroxyvitamin D (25[OH]D) cutoffs are not standardized and are not based on rigorous studies, so test sensitivities and specificities for detecting clinically important deficiency are currently unknown. This lack of a clear, validated threshold limits the use of single numeric test results as absolute criteria for coverage decisions.
Systematic reviews and randomized trials do not demonstrate that vitamin D supplementation reduces cancer incidence. The policy’s evidence summary states that current trials and meta‑analyses do not support supplementation for cancer prevention, and cited randomized studies did not show a consistent reduction in cancer incidence.
Recent guideline statements summarized in the policy recommend against universal screening. The Endocrine Society (2024) suggests against routine testing of 25(OH)D in general adult populations and in pregnant individuals who do not have other established indications, and the American College of Obstetricians and Gynecologists (ACOG) states there is insufficient evidence to recommend screening all pregnant women, advising testing be reserved for those thought to be at increased risk and interpreted individually.
Historic policy language documented in revisions previously described testing vitamin D levels in asymptomatic patients as not medically necessary when the enumerated criteria were not met. The revision history shows the addition of Item C (historic wording) and describes multiple past edits to Item A and B that defined covered patient populations and the prior not‑medically‑necessary stance for routine asymptomatic testing.
In the references‑only portion of the provided excerpt there are no explicit coverage exclusions enumerated beyond the policy statements themselves. The document does reference external guidance and a Noridian Local Coverage Determination (LCD L36692) for vitamin D assay testing for billing/coverage rules, but the reference list segment does not list additional explicit exclusions.
Testing asymptomatic individuals who do not meet the policy’s listed risk factors and who are not institutionalized is considered experimental/investigational and therefore not medically necessary under this policy. The policy explicitly states that testing in asymptomatic individuals is investigational when criteria in Items A and B are not met, reflecting the absence of direct evidence that routine testing improves clinical outcomes.
Routine testing of asymptomatic individuals lacks randomized controlled trial evidence showing that testing versus not testing improves clinical outcomes; therefore, routine screening in asymptomatic populations is judged to lack direct evidence of clinical benefit and may be considered investigational. The policy frames testing as clinically useful only when results will inform management decisions that improve net health outcomes.
The evidence summarized in this policy does not support the use of vitamin D supplementation specifically to prevent cancer incidence. Systematic reviews of RCTs noted that cancer outcomes were often not primary endpoints and, overall, did not demonstrate a reduction in incident cancer with vitamin D supplementation.
The policy cites professional guidance consistent with a non‑screening stance: the Endocrine Society (2024) recommends against routine 25(OH)D testing in several general adult populations and in pregnant individuals without indications, and ACOG (2011, reaffirmed 2024) advises that universal screening in pregnancy is not supported by current evidence and that testing should be individualized for those at increased risk.
Historic policy language within the document previously stated that testing vitamin D levels in asymptomatic patients was not medically necessary when the listed criteria were not met. Revision history entries document the addition of the not‑medically‑necessary language and prior changes to the policy items that defined covered and excluded populations.
Within the provided references‑only excerpt there are no explicit 'not medically necessary' statements beyond the policy body and its revision history; the reference list itself does not restate coverage determinations. For specific not‑medically‑necessary language, refer to the Policy section and the revision history entries.
Indications When Testing Is Covered
Diagnostic testing for suspected vitamin D deficiency or toxicity in symptomatic individuals when a listed high-risk condition is present; testing in asymptomatic individuals who are at risk or institutionalized
Laboratory covered indications Item A and Policy Guidelines.
Laboratory covered indications Item B.
Assessment when results would change management
No RCTs comparing testing vs no testing; clinical utility must be inferred from supplementation trials and management implications.
Assessment of baseline 25(OH)D status when evaluating need for supplementation or interpreting trial applicability
Many trials did not select patients by baseline 25(OH)D; documentation of baseline level is recommended when used to guide therapy.
Assessment of vitamin D status in research or clinical contexts related to asthma or pregnancy outcomes
Asthma and pregnancy sections reference multiple RCTs and reviews.
Pregnancy with increased risk for vitamin D deficiency, postmenopausal women and men 50+ for bone health monitoring, and other condition-specific indications supported by evidence or specialty guidance
Guideline-based and evidence-based indications summarized.
Testing in individuals with risk factors for vitamin D deficiency or specific listed clinical conditions (as outlined historically)
Revisions documented in the policy history.
Pregnancy and lactation — multiple randomized trials and reviews assessing vitamin D supplementation effects on maternal and neonatal outcomes are cited
Refer to pregnancy evidence tables and systematic reviews cited.
Asthma and respiratory disease — trials and meta-analyses on vitamin D supplementation for prevention or management of exacerbations and asthma control
Multiple SRs and RCTs cited in asthma sections.
Bone health, fractures, falls, cancer, cardiovascular and metabolic outcomes — numerous trials cited investigating supplementation effects
References cited span older adults and community populations.
Screening, diagnosis, and monitoring of vitamin D status as referenced by cited guidelines and trials
Guidelines and LCD cited in references.
Not Covered / Excluded Indications
The policy’s Not Covered summary states that routine population screening of asymptomatic individuals without risk factors or institutionalization is not covered and is considered experimental/investigational. This aligns with the policy language that testing of asymptomatic individuals is investigational when policy criteria for medical necessity are not met.
The policy emphasizes that there are no randomized trials demonstrating that testing for vitamin D deficiency versus not testing improves clinical outcomes; as a result, routine screening of the asymptomatic general population is not supported by direct evidence of benefit. This evidence gap underpins the not‑covered stance for routine population screening.
The evidence summarized in the policy does not support routine testing or supplementation solely for cancer prevention. Systematic reviews and RCTs cited in the references do not show a consistent reduction in cancer incidence attributable to vitamin D supplementation, and the policy therefore does not endorse testing for the purpose of cancer prevention.
Guideline statements referenced in the policy do not support universal screening: the Endocrine Society suggests against routine testing in general adult populations and pregnant individuals without indications, and ACOG states insufficient evidence to recommend universal pregnancy screening. These guideline positions support the policy’s not‑covered conclusions for routine screening in asymptomatic adults and pregnant individuals without other indications.
The policy’s historical language previously characterized testing in asymptomatic patients without risk factors as not medically necessary, and portions of those statements were revised; the revision history documents changes including the 02‑26‑2026 change of Policy Statements C and D from 'not medically necessary' to 'experimental/investigational.'
The provided references segment does not enumerate specific tests or indications labeled explicitly as not covered; in this excerpt there are no explicit not‑covered test lists. The policy body and laboratory not‑covered section supply the coverage stance for routine screening.
No explicit exclusions are listed in the references excerpt itself; the policy references external guidance and the Noridian LCD (L36692) for vitamin D assay testing. Providers should refer to the full policy text and the Noridian LCD for any explicit exclusions or billing rules not present in this excerpt.
Procedure and Diagnosis Codes
| multiple ICD-10 codes and ranges | Numerous ICD-10 diagnosis codes have been added, removed, or revised across policy updates; see Coding section revision history for specific codes and effective dates. |
| L36692 | Noridian LCD: Vitamin D Assay Testing (referenced as local coverage determination) |
Provider Actions, Documentation, and Billing Notes
Benefit verification required
Verify the member's benefits and any applicable prior authorization requirements with BCBSKS Customer Service and the member's contract before ordering vitamin D testing.
- Check member contract language for coverage or exclusions.
- Contact BCBSKS Customer Service for benefit verification and prior authorization rules.
Prior authorization considerations
Recognize that no randomized controlled trials directly compare testing versus no testing; use evidence from supplementation trials only as indirect support when determining whether testing will change management.
- Order testing only when results are expected to influence clinical management.
- Document clinical rationale linking testing to a management decision.
No prior auth specified
No prior authorization requirements are specified within the policy text; however, benefit verification per the member contract remains necessary.
- Absence of a stated PA in this policy does not waive member-contract PA rules.
- Confirm with payer if local plan or LCD imposes PA.
Prior authorization not addressed in this excerpt
The evidence-summary sections do not specify prior authorization requirements; they summarize clinical evidence and policy stance rather than PA procedures.
- Clinical evidence summaries should not be interpreted as PA policy.
- Follow member contract and payer PA processes.
Coding tied to policy coverage
The policy ties listed CPT/HCPCS codes to the Policy section: these codes are medically necessary only when testing meets the Policy's clinical criteria and any applicable member contract rules.
- Do not assume code inclusion guarantees reimbursement; ensure indication aligns with Policy criteria.
- Document how the test meets the Policy to support billing.
Prior authorization (not specified in this segment)
The policy references external citations but does not describe prior authorization in the reference list; verify PA requirements separately per contract and payer processes.
- Reference lists do not substitute for PA policy statements.
- Confirm any PA rules that may be in source documents or LCDs.
Follow Noridian LCD for coverage requirements
Follow Noridian Local Coverage Determination (LCD L36692) for Vitamin D Assay Testing where applicable; LCD requirements for prior authorization or billing may apply and failure to meet LCD requirements could lead to claim denial.
- Consult LCD L36692 for coverage and billing rules when Medicare or LCD jurisdiction applies.
- Ensure documentation meets any LCD-specified criteria.
Step therapy
No step therapy requirements are specified in this policy excerpt.
- No prerequisite treatments or trials are mandated by this document before testing.
Dose and safety considerations
Evidence on vitamin D supplementation includes dose-response and safety signals (for example, some very high-dose regimens increased falls); consider these safety findings when planning supplementation and when interpreting the need for testing.
- Trials reported reduced fractures with 700–800 IU/day in some analyses, while very high or certain bolus regimens were associated with increased falls or fractures.
- Use trial dosing and safety data to inform clinical decisions rather than assuming higher dosing is safer.
Required documentation
Document clinical signs/symptoms, the relevant diagnosis or high-risk condition, and any pertinent biochemical abnormalities (e.g., unexplained calcium, phosphorus, alkaline phosphatase, or parathyroid hormone) to support medical necessity for vitamin D testing.
- Include clinical diagnosis (eg, osteomalacia, rickets, osteoporosis) or biochemical reason for testing.
- Record benefit verification and any PA determinations in the medical record.
Test validity and interpretation
Recognize that there is no consensus reference standard or standardized cutoffs for 25(OH)D; document interpretation plans and acknowledge that available cutoffs are not universally validated.
- State which cutoff or reference range is being used and why it applies to the patient.
- Note limitations of test sensitivity and specificity in the record when relevant to coverage discussions.
Baseline 25(OH)D reporting
When baseline 25(OH)D levels are relevant to clinical decisions or to interpret trial applicability, document the baseline value in the medical record; many trials reported baseline levels and subgroup effects depended on baseline status.
- Record pre-supplementation 25(OH)D when assessing need for supplementation or monitoring response.
- Note if prior trials or guideline recommendations referenced baseline thresholds to guide therapy.
Documentation requirement
Include documentation demonstrating the test indication aligns with the Policy section (i.e., that the patient meets a listed high‑risk condition or is an at‑risk/institutionalized asymptomatic individual) to support medical necessity and billing.
- Attach clinical notes showing the listed high-risk condition or reasons testing will change management.
- Ensure the medical record supports the CPT/HCPCS code billed.
Denial risk for screening or unsupported testing
Testing vitamin D levels in asymptomatic individuals without the policy-listed risk factors or institutionalization carries a denial risk because such testing is considered experimental/investigational under this policy.
- Order testing for asymptomatic patients only if they meet criteria in Item A or B of the Policy.
- Anticipate claim denials if documentation does not show a listed indication.
Lack of direct evidence for testing utility
There are no randomized trials demonstrating that testing for vitamin D deficiency versus not testing improves clinical outcomes; this lack of direct evidence may be used to justify denials when testing is not clearly indicated.
- Be prepared to justify how testing will alter management and improve outcomes when requesting authorization.
- Cite clinical indication and expected management change in documentation to mitigate denial risk.
Medical necessity tied to policy criteria
The CPT/HCPCS codes listed in the policy do not by themselves guarantee coverage or reimbursement; the procedure must meet the Policy section criteria and member contract terms.
- Do not rely on code listing alone—ensure clinical criteria are met and documented.
- If denied, reference how the indication meets Policy criteria in an appeal.
Ordering Requirements and Frequency
ORDERING: Verify member benefits
Verify member benefits and follow member contract provisions when ordering tests; confirm prior authorization requirements with BCBSKS Customer Service as instructed in Policy Guidelines.
ORDERING: Test when results will change management
Order 25(OH)D testing only when results are expected to affect clinical management (for example symptomatic patients, those with listed high‑risk conditions, or asymptomatic but at‑risk/institutionalized individuals).
- Testing appropriate when it will change management or guide supplementation
- Use clinical context (signs/symptoms, biochemical markers, risk factors) to justify testing
ORDERING: No provider-type restriction stated
This excerpt does not impose specific ordering provider restrictions; follow local practice and member contract terms regarding who may order testing.
ORDERING: Who may order and frequency not specified
The provided excerpt does not specify who may order 25(OH)D testing or any frequency limits; rely on Policy Guidelines and member contract for such details.
ORDERING: Clinician types not specified
The policy excerpt does not specify clinician types that may order testing; guideline statements suggest clinicians managing pregnancy or bone health should consider testing when clinically indicated.
ORDERING: Historic allowance for testing in at‑risk asymptomatic patients
Historically, the policy allowed testing in certain asymptomatic populations with risk factors or institutionalized patients; document the specific risk factors or institutional status when ordering.
- Item B allows testing in individuals with listed risk factors and institutionalized patients
- Ensure documentation shows the patient meets Item A or B criteria
ORDERING: No who‑can‑order restrictions in excerpt
No 'who can order' restrictions are included in the provided references portion of the policy; follow local protocols and member contract rules.
ORDERING: Liaison committee implications on ordering
Liaison committee inputs from Internal Medicine, OB/GYN, and Family Practice suggest ordering is expected from primary care and specialty clinicians managing the listed conditions; document clinical rationale accordingly.
Key Definitions
Background and Rationale
Vitamin D (calciferol) is a fat‑soluble vitamin important for calcium homeostasis and bone metabolism, and serum 25‑hydroxyvitamin D (25[OH]D) is the biomarker most commonly used to assess vitamin D status. Deficiency is common and can result from inadequate intake, limited sun exposure, malabsorption, or organ dysfunction; testing is intended to guide treatment decisions that improve net health outcomes.
Revision and Policy Changes
Policy statements C and D were changed from 'not medically necessary' to 'experimental / investigational'.
Multiple Item A entries were added/modified (including adding chronic use of anticonvulsant medications or corticosteroids, adding hypo- or hypercalcemia, obstructive jaundice, osteogenesis imperfecta, osteosclerosis/osteopetrosis) and Items B and C were added clarifying asymptomatic testing criteria and a not medically necessary statement when criteria are not met.
Updated Rationale and References sections and changed wording in Section C ('is' to 'are'); ICD-10 codes were changed to code ranges in the Coding section.
Updated Description, Rationale, and References sections.
Updated Description, Rationale, References, and Coding sections; removed certain ICD-10 codes.
Updated Description, Rationale, and References sections.
The references‑only segment reiterates that no explicit not‑covered tests are listed within that portion. The policy text and revision history provide the applicable coverage and not‑covered statements; for additional exclusions or operational details, the full policy body and referenced LCDs should be consulted.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.